Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Alzheimer's Disease

Free Subscription 30.03.2026 1 Acta Neuropathol 8 Alzheimers Dement 1 Brain 2 Curr Alzheimer Res 2 Geriatrics (Basel) 18 J Alzheimers Dis 1 J Am Geriatr Soc 1 J Clin Psychiatry 1 J Neurol 1 J Neuropsychol 2 Lancet 2 Lancet Neurol 1 Neurobiol Aging 2 Neurochem Res 1 Neurology 1 Neuropsychology 1 Neuroreport 3 Neuroscience 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Acta Neuropathol

1. PASCUAL JR, Rivera I, Nguyen H, Ngo PT, et al
   Neuropathological measures of increased tau phosphorylation across the Down syndrome lifespan.
   Acta Neuropathol. 2026;151:28.
   PubMed         Abstract available
   
   

   
   Alzheimers Dement

2. LINDBOHM JV, Strazar M, Lee HM, Ashenberg O, et al
   Population and single-cell analyses reveal immune cell-specific expression profiles associated with Alzheimer's disease risk.
   Alzheimers Dement. 2026;22:e71282.
   PubMed         Abstract available
   
   
3. WEIGAND AJ, Tsoy E, Atkins KJ, Jarrott S, et al
   Classifying cognitive status with TabCAT Match and UDS executive function tests.
   Alzheimers Dement. 2026;22:e71299.
   PubMed         Abstract available
   
   
4. CHATILA ZK, Duggan MR, Silberberg E, Fernandez J, et al
   Can we refute a role for infections in Alzheimer's disease pathogenesis?
   Alzheimers Dement. 2026;22:e71288.
   PubMed         Abstract available
   
   
5. JAMALI A, Sisara MA, Nasab EK, Van Dam D, et al
   G-ALPS: An index for evaluating cognitive decline and aging using diffusion tensor imaging.
   Alzheimers Dement. 2026;22:e71118.
   PubMed         Abstract available
   
   
6. SHINER T, Nathan T, Levy MH, David AB, et al
   Alpha-synuclein co-pathology in a real-world early Alzheimer's disease cohort.
   Alzheimers Dement. 2026;22:e71240.
   PubMed         Abstract available
   
   
7. ROSA-GRILO M, Mallon D, Thomas DL, Beament M, et al
   Accelerated 3D MRI for ARIA monitoring in Alzheimer's disease.
   Alzheimers Dement. 2026;22:e71297.
   PubMed         Abstract available
   
   
8. LIU S, Bush WS, Kunkle BW, Byrd GS, et al
   Dissecting Alzheimer's disease heritability across populations.
   Alzheimers Dement. 2026;22:e71236.
   PubMed         Abstract available
   
   
9. XU Z, Mijalkov M, Sun J, Chang YW, et al
   Mapping individual molecular connectomes in Alzheimer's disease.
   Alzheimers Dement. 2026;22:e71310.
   PubMed         Abstract available
   
   

   
   Brain

10. YOUNG CB, Sheng J, Winer JR, Cody K, et al
    Longitudinal trajectories of divergent cortical tau patterns in preclinical Alzheimer's disease.
    Brain. 2026 Mar 26:awag113. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Curr Alzheimer Res

11. ZHANG Y, Li Z, Li H, Zhang K, et al
    Research on Alzheimer's Disease Risk Assessment Models and Biomarker Screening Based on Bioinformatics Analysis and Machine Learning Algorithms.
    Curr Alzheimer Res. 2026 Mar 24. doi: 10.2174/0115672050425330260122093903.
    PubMed         Abstract available
    
    
12. HU G, Zhang M
    Efficacy and Safety of Donanemab in the Treatment of Alzheimer's Disease: A Systematic Review and Meta-Analysis.
    Curr Alzheimer Res. 2026 Mar 23. doi: 10.2174/0115672050425914260119063736.
    PubMed         Abstract available
    
    

    
    Geriatrics (Basel)

13. ALKAM T, Tarshizi E, Benschoten AHV
    Risk Stratification for In-Hospital Mortality in Alzheimer's Disease Using Interpretable Regression and Explainable AI.
    Geriatrics (Basel). 2026;11:23.
    PubMed         Abstract available
    
    
14. CAO Y, Lee J, Seol J, Tsunoda K, et al
    Dose-Response Relationship Between Sleep Regularity Index and Stage-Specific Alzheimer's Disease: Cross-Sectional Evidence from Japanese Adults.
    Geriatrics (Basel). 2026;11:32.
    PubMed         Abstract available
    
    

    
    J Alzheimers Dis

15. DORFSMAN DA, Cai D, Hamilton-Nelson KL, Adams LD, et al
    Educational attainment is associated with reduced functional decline in Puerto Ricans with elevated pTau181.
    J Alzheimers Dis. 2026;110:685-695.
    PubMed         Abstract available
    
    
16. TORRES ER, Lopez ED, McBurrows L, Kollmorgen G, et al
    Physical activity across the life course and neural biomarkers.
    J Alzheimers Dis. 2026;110:810-820.
    PubMed         Abstract available
    
    
17. UEDA M, Suzuki T, Yoshimizu T, Konuma T, et al
    Cerebral glucose uptake and cognitive functions: A phenome-wide Mendelian randomization study.
    J Alzheimers Dis. 2026;110:895-908.
    PubMed         Abstract available
    
    
18. VERMA K, Kumar S
    From autopsy to PET to cerebrospinal fluid to blood: Quantifying reference-standard dependence in Alzheimer's disease amyloid biomarker validation.
    J Alzheimers Dis. 2026 Mar 22:13872877261430858. doi: 10.1177/13872877261430858.
    PubMed         Abstract available
    
    
19. 
    Corrigendum to "Neuropsychiatric signs and symptoms clusters and regional amyloid on (18)F-FC119S PET in Alzheimer's disease".
    J Alzheimers Dis. 2026 Mar 22:13872877261423686. doi: 10.1177/13872877261423686.
    PubMed        
    
    
20. KAMALIZONOUZI S, Amanollahi M, Farshbafnadi M, Dolatshahi M, et al
    Association between retinal neurodegeneration assessed by optical coherence tomography and PET-detected cerebral amyloid burden in Alzheimer's disease: A systematic review.
    J Alzheimers Dis. 2026 Mar 23:13872877261433198. doi: 10.1177/13872877261433198.
    PubMed         Abstract available
    
    
21. ZHOU C, Ji Y, Wang Y, Liang Y, et al
    Meta-analysis of the efficacy of interventions for persons living with Alzheimer's disease: The role of music therapy.
    J Alzheimers Dis. 2026 Mar 23:13872877261433196. doi: 10.1177/13872877261433196.
    PubMed         Abstract available
    
    
22. RISSANEN JA, Karkkainen S, Katisko K, Vanninen A, et al
    The performance of plasma pTau181 and pTau217 in distinguishing Alzheimer's disease from various neurodegenerative disorders, psychiatric disorders, and cognitively unimpaired controls.
    J Alzheimers Dis. 2026 Mar 23:13872877261431800. doi: 10.1177/13872877261431800.
    PubMed         Abstract available
    
    
23. TALLAPRAGADA B, Markovic SJ, Marston KJ, Brown BM, et al
    Composite scores to detect and monitor cognitive dysfunction in preclinical and prodromal Alzheimer's disease: A narrative review.
    J Alzheimers Dis. 2026 Mar 23:13872877261433044. doi: 10.1177/13872877261433044.
    PubMed         Abstract available
    
    
24. FISHER DW, Mehta R, Morrow CB, Kerr KF, et al
    Affective neuropsychiatric symptom metrics in the National Alzheimer's Coordinating Center dataset.
    J Alzheimers Dis. 2026 Mar 25:13872877261427462. doi: 10.1177/13872877261427462.
    PubMed         Abstract available
    
    
25. PENNINGTON C, Apurva P, Chen A, Duncan A, et al
    Disease modifying treatments for Alzheimer's disease: Clinician perspectives.
    J Alzheimers Dis. 2026 Mar 25:13872877261429859. doi: 10.1177/13872877261429859.
    PubMed         Abstract available
    
    
26. LUCA A, Piccoli T, Tomaselli A, Di Marco S, et al
    Cognitive and behavioral determinants of burden in caregivers of patients with Alzheimer's disease: A focus on sex and gender. The SexDemCare Multicentric Italian Study.
    J Alzheimers Dis. 2026 Mar 25:13872877261435213. doi: 10.1177/13872877261435213.
    PubMed         Abstract available
    
    
27. TAVAN Y, Roozegar S, Mohammadi ZF, Akbari A, et al
    Aerobic exercise significantly alters Notch1 signaling in a neurotoxic hippocampal rat model of Alzheimer's disease.
    J Alzheimers Dis. 2026 Mar 25:13872877261434058. doi: 10.1177/13872877261434058.
    PubMed         Abstract available
    
    
28. GARCIA DE LA GARZA A, Wang C, Derby CA, Gao Q, et al
    Generalizability of blood-based biomarkers of Alzheimer's disease and related dementias in a multicultural cohort of older adults: The effect of adjustment for kidney function.
    J Alzheimers Dis. 2026 Mar 25:13872877261426582. doi: 10.1177/13872877261426582.
    PubMed         Abstract available
    
    
29. KORIC L, Mourre H, Trompette C, Brillant L, et al
    Enhancing atypical Alzheimer's disease phenotyping through the oculomotor window in posterior cortical atrophy.
    J Alzheimers Dis. 2026 Mar 26:13872877261435137. doi: 10.1177/13872877261435137.
    PubMed         Abstract available
    
    
30. PARK J, Kwon HJ, Joo J, Jang H, et al
    Sex-specific accelerated epigenetic aging in the Alzheimer's disease spectrum.
    J Alzheimers Dis. 2026 Mar 26:13872877261431795. doi: 10.1177/13872877261431795.
    PubMed         Abstract available
    
    
31. LABERNEDE F, Lausecker A, Sanna L, Philippi N, et al
    Language performances in dementia with Lewy bodies and Alzheimer's disease: A longitudinal comparative study of naming and fluency.
    J Alzheimers Dis. 2026 Mar 26:13872877261427500. doi: 10.1177/13872877261427500.
    PubMed         Abstract available
    
    
32. MAZZEO S, Lassi M, Padiglioni S, Vergani AA, et al
    Towards the development of a management protocol for subjective cognitive decline: Insights from a cross-sectional and longitudinal analysis of multimodal data from a memory clinic.
    J Alzheimers Dis. 2026;110:728-745.
    PubMed         Abstract available
    
    

    
    J Am Geriatr Soc

33. HOQUE A, Cuthel A, Grudzen CR, Shah MN, et al
    Emergency Departments Leading the Transformation of Alzheimer's and Dementia Care: Emergency Care Redesign.
    J Am Geriatr Soc. 2026 Mar 25. doi: 10.1111/jgs.70394.
    PubMed         Abstract available
    
    

    
    J Clin Psychiatry

34. KAPUSTIN D, Rashidi-Ranjbar N, Wang W, Binns MA, et al
    Neuropsychiatric Symptom Clusters and Their Association With Brain Structure in Alzheimer Disease.
    J Clin Psychiatry. 2026;87:25m16192.
    PubMed         Abstract available
    
    

    
    J Neurol

35. VRILLON A, Gotze K, Dumurgier J, Cognat E, et al
    Eligibility for lecanemab treatment in a French memory clinic setting.
    J Neurol. 2026;273:228.
    PubMed         Abstract available
    
    

    
    J Neuropsychol

36. LAPLUME AA, Mellah S, Rajah MN, Belleville S, et al
    Educational attainment mitigates hippocampal-related episodic memory decline in individuals at risk of Alzheimer's disease.
    J Neuropsychol. 2026 Mar 24. doi: 10.1111/jnp.70039.
    PubMed         Abstract available
    
    

    
    Lancet

37. SCHNEIDER LS
    Semaglutide for Alzheimer's disease after evoke and evoke.
    Lancet. 2026 Mar 19:S0140-6736(26)00514-3. doi: 10.1016/S0140-6736(26)00514.
    PubMed        
    
    
38. CUMMINGS JL, Atri A, Sano M, Zetterberg H, et al
    Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.
    Lancet. 2026 Mar 19:S0140-6736(26)00459-9. doi: 10.1016/S0140-6736(26)00459.
    PubMed         Abstract available
    
    

    
    Lancet Neurol

39. MATTSSON-CARLGREN N, Palmqvist S, Horie K, Barthelemy N, et al
    Integration of plasma eMTBR-tau243 and p-tau217 in the diagnosis and stratification of Alzheimer's disease: a prospective cohort study.
    Lancet Neurol. 2026;25:357-367.
    PubMed         Abstract available
    
    
40. ASHTON NJ
    Biologically informed blood testing in Alzheimer's disease.
    Lancet Neurol. 2026;25:327-329.
    PubMed        
    
    

    
    Neurobiol Aging

41. KERSLAKE LD, Noonan C, Davies DS, Kim D, et al
    Ferritin-positive microglial clusters associate with microvessels and markers of vascular injury in MCI and Alzheimer's disease.
    Neurobiol Aging. 2026;163:46-62.
    PubMed         Abstract available
    
    

    
    Neurochem Res

42. SOME A, Naskar N, Thomas DM, Jeengar MK, et al
    Senescence as a Central Node in Alzheimer's Disease: Molecular Triggers, Cellular Effectors, and RNA-Based Interventions.
    Neurochem Res. 2026;51:116.
    PubMed         Abstract available
    
    
43. CHEN Y, Zhang D, Zhang Q, Li Q, et al
    Cofilin-1 Exacerbates Tau-Induced Mitochondrial Damage, Oxidative Stress, and Apoptosis in Alzheimer's Disease.
    Neurochem Res. 2026;51:118.
    PubMed        
    
    

    
    Neurology

44. NOGUCHI-SHINOHARA M, Ono K
    Successful Amyloid Removal by Donanemab Treatment in a Female Patient With Alzheimer Disease: A Case Report.
    Neurology. 2026;106:e214817.
    PubMed        
    
    

    
    Neuropsychology

45. ZHANG M, Cui Q, Lu Y, Pan Y, et al
    A large language model-based self-learning and critical agent framework for multimodal Alzheimer's disease diagnosis.
    Neuropsychology. 2026 Mar 26. doi: 10.1037/neu0001079.
    PubMed         Abstract available
    
    

    
    Neuroreport

46. KANG J, Du X, Zhang X, Li Y, et al
    METTL3-mediated TIGAR m6A modification and its role in microglia activation related to Alzheimer's disease.
    Neuroreport. 2026;37:195-203.
    PubMed         Abstract available
    
    

    
    Neuroscience

47. YANG C, Qi W, Li W, Liang F, et al
    Gut microbiota transmission induces cognitive impairment through amyloid pathology in wild-type mice.
    Neuroscience. 2026;600:104-111.
    PubMed         Abstract available
    
    
48. LI A, Peng W, Wu B, Li C, et al
    Therapeutic efficacy of engineered exosomes in Alzheimer's disease: A systematic review and meta-analysis of preclinical animal models.
    Neuroscience. 2026 Mar 20:S0306-4522(26)00187.
    PubMed         Abstract available
    
    
49. HARUTYUNYAN H, Minasyan R, Kalueff AV, Yenkoyan KB, et al
    Neurobiological links between Alzheimer's disease and reward system dysfunction.
    Neuroscience. 2026;603:57-68.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

50. MOSCONI M, Leonardi C, Armour-Garb Z, Rocutto B, et al
    Tau catalyzes amyloid-beta aggregation and toxicity in a polymorph-dependent manner.
    Proc Natl Acad Sci U S A. 2026;123:e2532775123.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum